IndraLab
Statements
MINDY3 activates bortezomib. 1 / 1
|
1
reach
"Since, CCAR1 and CARP -1 is an emerging and novel target of diverse cell growth and apoptosis signaling pathways [XREF_BIBR, XREF_BIBR - XREF_BIBR] and is not involved in cisplatin dependent HBC growth inhibition [XREF_BIBR], our identification of novel Velcade targets such as CCAR1 and CARP -1 has potential to allow for design of effective anti-MPM strategies for optimizing Velcade utility in a range of MPM including the drug (Cisplatin)-resistant phenotype."